COVID-19 can leave behind small spots on the lungs, called pulmonary nodules, that show up on CT scans weeks or months after the infection has cleared. These nodules are overwhelmingly benign, formed by lingering inflammation, scarring, or organizing pneumonia, but they create a genuine diagnostic puzzle because they can look unsettlingly similar to early-stage lung cancer on imaging. A multicenter study found that the detection rate of solid lung nodules rose significantly in the post-pandemic period compared to before COVID-19 appeared, making this a widespread concern for both patients and doctors navigating follow-up care.
Why COVID-19 Leaves Nodules Behind
When SARS-CoV-2 infects the lungs, it damages the thin lining of the air sacs. The body’s repair response often overshoots, filling those damaged areas with inflammatory tissue rather than returning them cleanly to normal. The most common pattern behind post-COVID nodules is organizing pneumonia, a condition in which plugs of inflammatory tissue fill the small airways and surrounding lung. Clinical and radiological evidence has confirmed that organizing pneumonia is a recognized consequence of SARS-CoV-2 infection.1PubMed Central. The Hidden Pandemic of COVID-19-Induced Organizing Pneumonia These plugs can appear as nodules or patchy areas on a CT scan, and they may persist long after the virus itself is gone.
The lung’s response to COVID-19 follows a spectrum. Mild and reversible cases tend to produce nonspecific pneumonia or organizing pneumonia patterns. More severe cases can progress to diffuse alveolar damage followed by fibrosis, which is essentially permanent scarring. These pathological responses are not unique to SARS-CoV-2; they are the lungs’ universal reaction to serious viral pneumonia.2PubMed Central. An Integrated Radiologic-Pathologic Understanding of COVID-19 Pneumonia That shared biology is one reason post-COVID nodules are so hard to distinguish from other causes on imaging alone.
Beyond organizing pneumonia and fibrosis, SARS-CoV-2 can trigger a broader immune dysregulation that opens the door to other nodule-forming conditions. Some patients develop sarcoidosis-like granulomatous inflammation after COVID-19, where clusters of immune cells form tiny lumps in the lung tissue. Research has documented distinct immune-cell shifts in sarcoidosis patients who previously had COVID-19, with higher levels of certain inflammatory T-cell subsets compared to sarcoidosis patients without a COVID-19 history.3PubMed Central. Immune responses in pulmonary sarcoidosis following COVID-19 Whether COVID-19 causes sarcoidosis outright or merely unmasks it in people who were already predisposed remains an open question, but the clinical overlap adds another layer to the differential diagnosis of post-COVID lung nodules.
How Common Are Post-COVID Lung Nodules
More common than most people expect. A multicenter retrospective study covering nearly 19,000 subjects found that pulmonary nodules were detected in about 61% of all study participants undergoing screening. The overall detection rate of nodules rose in the post-pandemic group compared to the pre-pandemic group, and the increase was driven specifically by solid nodules. Ground-glass nodules, mixed nodules, and calcified nodules did not show a statistically significant change. The study also found that the detection rate of fibrotic lesions climbed significantly after the pandemic began.4PubMed Central. Analysis of screen-detected pulmonary nodules before and after the novel coronavirus epidemic: a multicenter retrospective cohort study
That jump in solid nodule detection does not mean all of those nodules are directly caused by COVID-19 infection. Some of the increase reflects the fact that far more people received chest CT scans during and after the pandemic than before it, whether for COVID-19 diagnosis, follow-up, or unrelated reasons. More scanning inevitably means more incidental findings. But the selective rise in solid nodules and fibrotic lesions, rather than all nodule subtypes equally, suggests that post-infectious inflammation and scarring genuinely contributed to the trend.
What These Nodules Actually Look Like
Post-COVID lung nodules can take several forms on a CT scan, and that variety is part of what makes them tricky. The most common appearances include:
- Ground-glass opacities: Hazy, translucent areas that do not fully obscure the underlying lung structure. These are the hallmark of active or resolving inflammation.
- Solid nodules: Dense, well-defined spots that can represent organized scar tissue, resolving infection, or occasionally something more concerning.
- Mixed nodules: A combination of ground-glass and solid components, sometimes called part-solid nodules.
- Fibrotic bands or reticular changes: Scar-like streaks that reflect permanent tissue remodeling, often accompanied by mild distortion of the surrounding lung architecture.
A follow-up study of patients recovering from COVID-19 pneumonia found that some form of residual lung change persisted in the vast majority of cases. Roughly 92% of follow-up CT scans showed at least one abnormality, most commonly ground-glass opacities (58%), consolidation (about 45%), and thickening of the tissue between lung lobules (about 41%). Fibrosis was seen in about 17% and bronchiectasis, a permanent widening of the airways, in about 15%. Complete resolution was seen in only 8% of patients, and those tended to be younger.5Polish Journal of Radiology. Post-COVID-19 sequelae in lungs: retrospective computed tomography analysis in selected tertiary care hospitals of Mangalore
The Diagnostic Puzzle of Scar Versus Cancer
This is where post-COVID nodules become genuinely anxiety-inducing. A residual ground-glass opacity left behind after COVID-19 pneumonia can look nearly identical to an early-stage lung adenocarcinoma on high-resolution CT. Both can appear as a localized hazy spot, and both can show features like tiny air pockets (vacuoles), pulling on the pleural lining, and invasion of nearby blood vessels. As researchers have noted, high-resolution CT alone is often not enough to reliably distinguish a COVID-19 scar from a cancer.6PubMed Central. Ground glass opacities of the lung before, during and post COVID-19 pandemic The diagnostic challenge grows when a patient has multiple residual opacities, raising the question of whether they are all post-infectious scars or whether an early cancer is hiding among them.
COVID-19 pneumonia has also been documented presenting with multiple solid nodules that mimicked metastatic cancer on imaging. In one reported case, a 45-year-old woman with confirmed COVID-19 had CT findings so suggestive of widespread metastatic disease that the initial clinical concern was cancer, not infection.7Journal of the Belgian Society of Radiology. COVID-19 Pneumonia Presenting with Multiple Nodules Mimicking Metastases: An Atypical Case Cases like this underline why clinical context matters so much. A nodule appearing for the first time on a scan performed during or shortly after a COVID-19 infection, in a patient without prior imaging showing the same spot, deserves a period of watchful follow-up before anyone rushes to biopsy.
During the pandemic, expert panels recommended that surveillance CT scans for previously detected lung nodules could reasonably be delayed by about three to six months when immediate scanning posed logistical or infection-control challenges.8PubMed Central. Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic: CHEST Expert Panel Report That guidance has since been relaxed as pandemic-era constraints eased, but the principle it reflects remains relevant: most small, stable nodules, whether COVID-related or not, are safe to monitor over time rather than biopsy immediately.
Do Post-COVID Nodules Go Away on Their Own
Many do, especially in milder cases. Organizing pneumonia nodules are fundamentally inflammatory, and once the immune system calms down, those nodules often shrink or disappear over weeks to months. In one reported case, a patient who developed multiple bilateral solid nodules (all under 1 cm) after mild COVID-19 pneumonia saw progressive resolution of those nodules on repeat imaging at three months, aided by a low dose of prednisone.9Archivos de BronconeumologÃa. Multiple Solid Nodules at Post-COVID-19 Follow-Up After Mild Pneumonia
But resolution is far from guaranteed. As noted earlier, the Mangalore follow-up study found complete clearing in only 8% of patients, with the rest retaining some degree of residual change. The likelihood of full resolution depends on several factors: younger patients fare better, milder initial disease is associated with less persistent scarring, and the type of residual change matters. Ground-glass opacities are more likely to fade than established fibrosis, which tends to be permanent. If a nodule has not changed in size or density after six to twelve months of monitoring, it is considered stable and unlikely to be malignant, though fibrotic remnants may linger indefinitely on future scans.
When Steroids Help
For patients whose post-COVID lung changes involve active organizing pneumonia rather than established fibrosis, corticosteroids can make a meaningful difference. Early initiation of steroid treatment in organizing pneumonia is associated with improved symptoms and outcomes, though a prolonged course is sometimes needed when COVID-19 is the trigger.10PubMed Central. Organizing Pneumonia: An Unusual Sequela of COVID-19 Infection
An observational study of 30 patients with persistent post-COVID interstitial lung disease who received prednisolone found substantial improvements. Lung function testing showed an average relative increase of about 32% in the lungs’ ability to transfer gas and roughly 10% in the volume of air the lungs could hold. All 30 patients reported that their breathlessness improved, and repeat imaging showed that the denser, more solid components of the lung changes resolved, leaving behind only subtler ground-glass patterns. At three weeks of follow-up imaging, none of the treated patients showed progression from inflammation to fibrosis.11PubMed Central. Persistent Post–COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment The timing matters: steroids work on active inflammation, not on mature scar tissue. A patient whose CT shows predominantly fibrotic changes months after infection is less likely to benefit.
Fungal Infections and Vascular Complications
Not every post-COVID lung nodule is a scar or a bit of leftover inflammation. COVID-19 can leave the immune system in a weakened or dysregulated state, and that window of vulnerability allows opportunistic infections to take hold. Invasive pulmonary aspergillosis, a severe fungal infection, has been increasingly recognized in patients recovering from COVID-19, particularly those who were immunocompromised or spent time on mechanical ventilation.12PubMed Central. Invasive pulmonary aspergillosis in the post-COVID-19 era: diagnosis, treatment, and what lies ahead Aspergillus infections can produce nodules, cavities, or consolidation on imaging, and they require antifungal treatment rather than steroids, so identifying them correctly is critical.
COVID-19 also carries a well-documented risk of blood clotting within the lungs. Small pulmonary thrombi, clots lodged in the lung’s blood vessels, can appear as nodule-like densities or areas of lung damage on imaging. In one fatal case, a patient with a previously asymptomatic COVID-19 history died from a large thrombus blocking the main pulmonary artery, with autopsy revealing widespread vascular clots and inflammatory changes throughout the lungs and other organs.13PubMed Central. Fatal pulmonary arterial thrombosis in a COVID-19 patient, with asymptomatic history, occurred after swab negativization While such extreme outcomes are rare, smaller clot-related lung changes are not uncommon after moderate-to-severe COVID-19 and can contribute to the constellation of findings on post-recovery imaging.
How AI Is Improving Nodule Identification
One of the most promising developments in managing post-COVID nodules is the application of radiomics, which uses computer algorithms to extract and analyze hundreds of measurable features from CT images that the human eye cannot reliably assess. A study specifically targeting COVID-19 lung nodules found that machine-learning models could distinguish COVID-19 nodules from other benign nodules with about 83% accuracy and from malignant nodules with about 88% accuracy, using features related to the texture and internal structure of the nodules.14PubMed Central. Radiomics analysis for distinctive identification of COVID-19 pulmonary nodules from other benign and malignant counterparts
A separate study focused on the broader question of benign-versus-malignant nodule classification found that texture-based radiomic features were the strongest predictors of malignancy. Using an advanced machine-learning algorithm, the model achieved about 89% accuracy in distinguishing benign from malignant nodules.15PubMed Central. Radiomics as a non-invasive adjunct to Chest CT in distinguishing benign and malignant lung nodules These tools are not yet replacing clinical judgment, but they are increasingly being studied as a way to help radiologists triage indeterminate nodules and potentially reduce unnecessary biopsies, which is especially relevant when COVID-19 has flooded the population with new, ambiguous lung findings.
Lower-Dose Scanning for Ongoing Monitoring
If you have post-COVID lung changes that need repeated imaging over months or years, cumulative radiation exposure from standard CT scans becomes a legitimate concern. A prospective study compared ultra-low-dose CT scans with standard-dose scans in post-COVID patients and found that ultra-low-dose scans delivered less than one-tenth of the radiation, roughly equivalent to just twice the dose of a standard chest X-ray taken from two angles. Despite the dramatic reduction in radiation, the ultra-low-dose scans maintained high accuracy in detecting post-COVID lung abnormalities.16PubMed Central. Ultra-low-dose vs. standard-of-care-dose CT of the chest in patients with post-COVID-19 conditions For the large number of people who recovered from COVID-19 and have residual findings that merit periodic surveillance, this is encouraging. It means long-term monitoring does not have to come with a meaningful radiation penalty.
How Vaccination Changes the Picture
Vaccination does not prevent lung involvement in breakthrough COVID-19 infections, but it appears to change the pattern and severity of what shows up on imaging. A study comparing CT findings in vaccinated and unvaccinated COVID-19 patients found that unvaccinated patients were roughly twice as likely to show certain aggressive-looking patterns on their scans. The crazy-paving pattern, which involves ground-glass opacity overlaid with thickened tissue lines and looks alarming on imaging, was significantly more common in unvaccinated patients even after adjusting for age, pre-existing diseases, and virus variant.17Scientific Reports. Pulmonary computed tomographic manifestations of COVID-19 in vaccinated and non-vaccinated patients
The practical implication is straightforward: vaccinated individuals who develop breakthrough COVID-19 tend to have milder lung involvement, which likely translates to fewer and less alarming residual nodules on follow-up imaging. This does not eliminate the possibility of post-COVID nodules in vaccinated people, but it shifts the odds toward milder residual changes and faster resolution.
How COVID-19 Lung Patterns Compare to Influenza
People sometimes wonder whether post-COVID lung nodules are unique to SARS-CoV-2 or part of a broader pattern seen after any serious respiratory virus. A comparative study of CT findings in COVID-19 pneumonia versus influenza pneumonia found considerable overlap. Both infections produced ground-glass opacities, consolidation, bronchial wall thickening, and interlobular septal thickening at similar rates. The key imaging differences were in distribution rather than type: COVID-19 lesions tended to sit closer to the pleural surface (the outer lining of the lung), while influenza was more likely to produce mucoid impaction and pleural effusion.18PubMed. CT Manifestations of Coronavirus Disease (COVID-19) Pneumonia and Influenza Virus Pneumonia: A Comparative Study The overlap confirms what pathology studies have shown: the lung’s repertoire of responses to viral injury is limited, and many post-infectious nodules from different viruses look remarkably similar. What sets COVID-19 apart is the sheer number of people affected, which has made post-viral lung nodules a population-level concern rather than an occasional finding.
The Emotional Weight of Finding a Spot on Your Lungs
The psychological side of lung nodule discovery is understudied and underappreciated. Regardless of cause, being told you have a spot on your lung triggers real distress. A study of patients with incidental pulmonary nodules found that nearly 60% met the threshold for anxiety on a standard screening questionnaire.19PubMed Central. Assessment of anxiety and depression in patients with incidental pulmonary nodules and analysis of its related impact factors Another study specifically examining emotional distress after nodule discovery found that about a third of patients reported mild distress, with an additional 9% reporting moderate and 7% reporting severe distress. Greater distress was linked to larger nodule size and, critically, to not being notified promptly by a doctor. Younger patients, women, smokers, and Black and Hispanic patients reported higher levels of distress and anxiety.20CHEST. Emotional Distress, Anxiety, and General Health Status in Patients With Newly Identified Small Pulmonary Nodules
For people finding out about lung nodules on a post-COVID follow-up scan, the anxiety is compounded by uncertainty about what the virus has done to their body. The single most effective anxiety-reducing factor in the research is timely, clear communication from a clinician. Being told “we see a small spot, it’s very likely from your recent COVID-19 infection, and here’s the plan for monitoring it” is measurably better for a patient’s mental health than learning about the nodule from a radiology portal or a delayed letter. If you’ve discovered a nodule on your own imaging report and haven’t heard from your doctor, calling to discuss it is worth the effort.